The earnings call reflects a positive sentiment overall, with significant achievements in EXPAREL volume growth, enhanced gross margins, strategic partnerships, and a strong financial position. However, there are concerns regarding stagnant sales for ZILRETTA and iovera°, increased operating expenses, and delays in the adoption of NOPAIN guidelines.

Company Guidance

During the Pacira Biosciences Q2 2025 earnings call, the company provided guidance emphasizing several key metrics. Notably, there was a 6% year-over-year volume growth for their flagship product, EXPAREL, marking the highest growth in eight quarters. The company narrowed its full-year revenue guidance to $730 million to $750 million, reflecting confidence in their commercial and clinical strategies. They also increased their guidance for non-GAAP gross margins to a range of 78-80% due to enhanced manufacturing efficiencies. Additional financial highlights included a new $300 million revolving credit facility and a $50 million repurchase of common stock, signaling a strategic focus on capital allocation. The company's 5x30 strategy, aiming for five strategic partnerships by 2030, was bolstered by a new collaboration with Johnson & Johnson MedTech for ZILRETTA, expected to significantly expand patient access. Overall, Pacira remains focused on its strategic imperatives of growing its commercial base and advancing its innovative pipeline.

EXPAREL Volume Growth

EXPAREL performance improved with 6% year-over-year volume growth, marking the highest in 8 quarters.

Enhanced Gross Margins

Non-GAAP gross margin improved to 82% versus 76% last year, benefiting from manufacturing efficiencies.

Strategic Partnership with J&J MedTech

Pacira executed a potentially transformative collaboration with Johnson & Johnson MedTech for ZILRETTA, expected to double sales calls for the product.

Strong Financial Position

Enhanced capital structure and liquidity with a new $300 million revolver and significant debt reduction.

Successful Share Repurchase

Disciplined capital allocation with the repurchase of $50 million of common stock.

Pacira Pharmaceuticals (PCRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PCRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.65 / -	0.79	―	―	―
Aug 05, 2025	2025 (Q2)	0.71 / 0.74	0.89	-16.85% (-0.15)
May 08, 2025	2025 (Q1)	0.60 / 0.62	0.62	0.00% (0.00)
Feb 27, 2025	2024 (Q4)	0.83 / 0.91	0.89	2.25% (+0.02)
Nov 06, 2024	2024 (Q3)	0.70 / 0.79	0.72	9.72% (+0.07)	―
Jul 30, 2024	2024 (Q2)	0.70 / 0.89	0.78	14.10% (+0.11)
May 07, 2024	2024 (Q1)	0.62 / 0.62	0.53	16.98% (+0.09)
Feb 29, 2024	2023 (Q4)	0.88 / 0.89	0.8	11.25% (+0.09)
Nov 02, 2023	2023 (Q3)	0.78 / 0.72	0.64	12.50% (+0.08)
Aug 02, 2023	2023 (Q2)	0.76 / 0.78	0.51	52.94% (+0.27)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PCRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$22.54	$22.40	-0.62%
May 08, 2025	$24.91	$25.12	+0.84%
Feb 27, 2025	$25.38	$24.05	-5.24%
Nov 06, 2024	$17.67	$17.70	+0.17%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pacira Pharmaceuticals (PCRX) report earnings?

Pacira Pharmaceuticals (PCRX) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Pacira Pharmaceuticals (PCRX) earnings time?

Pacira Pharmaceuticals (PCRX) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PCRX EPS forecast?

PCRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.65.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing